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Human peritoneal mesothelial cells (MC) play an important role in inﬂammatory processes of the peritoneal cavity by producing
various cytokines and chemokines, such as monocyte chemoattractant protein-1 (MCP-1). The present study was designed to
assess the eﬀect of the peroxisome proliferator-activated receptor-gamma- (PPARγ-) activator rosiglitazone on the mesothelial
MCP-1 expression and release. Primary cultures of MC were obtained from omental tissue. MCP-1 antigen concentrations were
measured in the cell supernatant by ELISA and MCP-1 mRNA levels by real-time polymerase chain reaction. The presence of
PPARγ onMCwasassayedinaWesternBlotanalysis.MCconstitutivelyexpressPPARγ.Activationofthisreceptorviarosiglitazone
(0,1–10μmol/L) resulted in signiﬁcantly reduced amounts of mesothelial MCP-1 release as well as MCP-1 mRNA. The use of the
PPARγ inhibitor GW-9662 could completely prevent the rosiglitazone eﬀects. Rosiglitazone was also eﬀective in reducing TNFα-
induced enhanced secretion of MCP-1. Our ﬁndings indicate that glitazones are eﬀective in reducing constitutive and TNFα-
stimulated mesothelial MCP-1 mRNA expression and release.
1.Introduction
Mesothelial cells (MC), which form the innermost mono-
layer of the peritoneal cavity, are critical in morphological
and functional alterations of the peritoneal membrane in
patients who undergo peritoneal dialysis (PD). They are a
major source of intraperitoneal monocyte chemoattractant
protein-1 (MCP-1) which is a chemokine that has been
reported to play a key role in the recruitment of monocytes
toward the peritoneal cavity [1]. Monocytes in turn con-
tribute to peritoneal ﬁbrosis by producing various cytokines
and growth factors [2] that induce cell proliferation and
extracellular matrix production in mesothelial cells and
ﬁbroblasts [3, 4].
Thiazolidinediones (TZD) are a novel group of antidi-
abetic agents that act via the activation of peroxisome
proliferator-activated receptor-gamma (PPAR-γ), a nuclear
hormone receptor. PPAR-γ regulates a variety of metabolic
pathways as a transcription factor [5]. Therefore, TZD like
rosiglitazone are not only capable of increasing the insu-
lin sensitivity in peripheral organs (as e.g., adipose tissue)
and thus lowering blood glucose levels in diabetic patients;
they also possess anti-inﬂammatory capacities in certain cir-
cumstances as they decrease the expression of inﬂammatory
proteins like iNOS and MMP9 in macrophages [6, 7]. A re-
duced expression of MCP-1 due to TZD treatment has been
shown for diverse cell types as, for example, lung epithelial
[8], endothelial [9], and mesangial cells [10]. In this context,
the present study was designed to investigate the presence of
PPAR-γ on human peritoneal MC and to characterize the
eﬀect of PPAR-γ activation by TZD on mesothelial MCP-1
mRNA transcription and release.2 Mediators of Inﬂammation
2.MaterialsandMethods
2.1. Materials. Medium M199 and newborn calf serum were
obtained from Gibco BRL (Eggenstein, Germany); tissue-
culture plates came from Costar (Cambridge, Massachusetts,
USA). Human serum was prepared from freshly collected
blood of healthy donors and stored at –20◦C. Fibronectin
fromhumanserum,trypsin,andTNFαwerepurchasedfrom
Boehringer (Mannheim, Germany), collagenase type II from
Worthington (Freehold, NY, USA).
Monoclonal antibodies against cytokeratins 8 and 18 as
well as vimentin were a gift from Dr. G. van Muijen (Univer-
sity of Nijmegen, The Netherlands). Antibody against PPAR-
γ was from Santa Cruz Biotechnology (Santa Cruz, Califor-
nia, USA). MTT was from Sigma-Aldrich (St. Louis, MO,
USA). Rosiglitazone was from Molekula (Nienburg/Weser,
Germany), and GW-9662 was purchased from Cayman
chemical (Ann Arbor, Michigan, USA).
2.2. Cell Culture Experiments. MC were isolated from the
omental tissue of consenting patients undergoing elective
surgery, as described previously [11]. The patients were free
from peritonitis or peritoneal carcinosis. Cells were grown
in ﬁbronectin-coated dishes in M199 medium supplemented
with 25mmol/L HEPES (pH 7.3), 2mmol/L glutamine, 10%
(v/v) human serum and 10% (v/v) newborn calf serum
(heat inactivated), penicillin (100IU/mL), and streptomycin
(100μg/mL) at 37◦C under 5% CO2/95% air atmosphere.
The medium was replaced every 2 to 3 days. Subcultures
were obtained by trypsin/EDTA treatment at a split ratio of
1:3. The cells were purely MC, as assessed by their uniform
cobblestone appearance at conﬂuence, by the absence of von
Willebrand factor, and by their uniform positive staining for
cytokeratins 8 and 18 as well as for vimentin. For the experi-
ments, conﬂuent cultures were used at the second or third
passage, and cells were refed with 2% human serum 24 hours
before the experiment. Conditioned media were obtained by
incubating cells in 2cm2 dishes at 37◦C with 0.5mL serum-
free M199 containing the appropriate concentration of the
test compound. Serum-free medium M199 served as a con-
trol. In coincubation experiments with TNFα,c e l l sw e r ep r e -
incubated for 24 hours with rosiglitazone, and then TNFα
wasadded.InexperimentsusingaPPAR-γ blocker,cellswere
preincubatedwithGW-9662for24hours.Supernatantswere
centrifuged 5 minutes at 2000×g to remove cells and cellular
debris,andthesampleswerefrozenat–20◦Cuntiluse.Allex-
periments were done with cells from 3 to 6 individual donors
and were measured in triplicate.
2.3. Western Blot Analysis. Cultured human mesothelial cells
were harvested with lysis buﬀer (50mM Tris-HCl pH7.4, 1%
Nonidet P-40, 0.25% sodium deoxycholate, 150mMNaCl,
1mMEGTA, and 1mM Na3VO4, Complete Protease
Inhibitor Cocktail (Roche, Mannheim, Germany)). Extract-
ed proteins were boiled in loading buﬀer for 30min, resolved
by 8% SDS-PAGE under reducing conditions, and transfer-
red to an Immobilon-P membrane (Millipore, Eschborn,
Germany). The membrane was blocked with 3% skim milk,
incubated in a 1:1000 dilution of a rabbit polyclonal IgG-
antibodyagainsthumanPPARγ-1(SC-7196,SantaCruzBio-
technology, Heidelberg, Germany) over night, and rinsed
with PBS containing 0.1% Tween 20. Immune complexes
were visualized using enhanced chemoluminescence (ECL,
Amersham Biosciences, Freiburg, Germany). Human breast
carcinoma cell lysate protein extract served as positive con-
trol for PPARγ-1 detection.
2.4. MTT Assay. Human mesothelial cells (30 × 103/100μL
medium) were cultured in 96-well microtiter plates for
24h under standard conditions to yield ﬁrmly attached and
stably growing cells. After discarding supernatants, 50μLo f
medium M199 containing rosiglitazone in concentrations of
1a n d1 0μg/L or medium M199 as a control was added to the
cells and incubated for 48h. Then 50μLo fa1m g / m Ls o l u -
tion of (3,5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetrazoli-
um bromide) MTT (SIGMA-ALDRICH, Taufkirchen, Ger-
many no. M2128) was added. After 3h incubation at 37◦C,
formazan crystals were dissolved by addition of 100μL
isopropanol and 0.04NHCl. Absorbance was then measured
at 590nm using a GENios plus TECAN ELISA reader. For
each experiment at least 6 wells were analyzed per experi-
mental condition.
2.5. MCP-1 Assay. MCP-1 antigen levels [pg/105 cells] were
measured by Quantikine human MCP-1 immunoassay from
R&D Systems (Minneapolis, MN, USA). Diluted aliquots of
thecellsupernatantswereassayedwithoutpriorpuriﬁcation.
2.6. RNA Isolation and Real-Time Quantitative RT-PCR.
Total RNA was extracted from cells using silica gel columns
(RNeasy, Qiagen, Hilden, Germany). 2μg of isolated total
RNA underwent random hexamer-primed reverse transcrip-
tion for one hour at 42◦C using a modiﬁed Molony murine
leukaemia virus (MMLV) reverse transcriptase (Superscript,
Life Technologies, Karlsruhe, Germany). Real-time quanti-
tative reverse transcription-polymerase chain reaction (RT-
PCR) was performed on a Taq-Man ABI 7700 Sequence
Detection System (PE Biosystems, Weiterstadt, Germany)
using heat-activated TaqDNA polymerase (Amplitaq Gold,
Applied Biosystems, Darmstadt, Germany). Thermal cycler
conditions contained holds for two minutes at 50◦Ca n d
ten minutes at 95◦C, followed by 40 cycles of 15 seconds at
95◦C and one minute at 60◦C. Message expression was cal-
culated following the ΔΔCt procedure [12]. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) and 18S ribosomal
RNA (rRNA) served as the reference housekeeping gene.
Controls consisting of H2O or samples that were not reverse
transcribed were negative for the target and reference. Seq-
uences with following gene bank accession numbers served
for the design of the predeveloped Taq Man assay reagents
(PDAR) or primers and probe, purchased from Ap-
plied Biosystems (Darmstadt, Germany): X14768 (human
MCP-1/CCL2) M33197 (human GAPDH) and X03205.1
(human18s-rRNA).Mediators of Inﬂammation 3
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Figure 1: Western Blot analysis of PPARγ-1 in two diﬀerent
isolatesounstimulatedmesothelialcells.Totalproteinwasextracted
from unstimulated peritoneal mesothelial cells or human breast
carcinoma cells (positive control) and were analysed using the
Western Blot technique. The amount of total protein loaded is
indicated. Pos. ctrl: positive control; neg. ctrl: negative control.
2.7. Statistical Analysis of the Data. Data are given as mean
± SD. Statistical analysis was performed using the ANOVA
analysis. A P value < 0.05 was considered to indicate statis-
tically diﬀerences.
3. Results
3.1. Detection of Constitutive PPAR-γ Expression in MC. We
evaluated the presence of PPAR-γ1 on human MC via West-
ern Blot. Analysis of the extracted total protein of unstimu-
lated MC showed a single band at 67kDa as has been
described for PPAR-γ1 and was comparable to the recom-
mended positive control (protein from human breast carci-
noma cells) (Figure 1).
3.2. Eﬀect of Rosiglitazone on the Secretion of MCP-1 in
Unstimulated MC. Conﬂuent unstimulated MC were in-
cubatedwithincreasingconcentrationsofrosiglitazone(0.1–
10μmol/L) for 48 hours. This resulted in a concentra-
tion-dependent decrease of MCP-1 protein levels in the cell
culture supernatants. Rosiglitazone treatment reached statis-
tical signiﬁcancy at each employed concentration: A con-
centration of 0.1μmol/L reduced the MCP-1 level to
13200pg/105 cells versus control 18200pg/105 cells (P =
0.013) whereas a concentration of 1μmol/L reduced MCP-1
levels to 12700pg/105 cells (P = 0.001) and a concentration
of 10μmol/L to 9400pg/105 cells (P<0.001) (Figure 2(a)).
Rosiglitazone treatment in the shown concentrations did not
eﬀect cell viability as assessed in trypan blue staining or cell
proliferation as assessed in an MTT assay (Figure 3).
3.3. Eﬀect of Rosiglitazone on the MCP-1 mRNA Levels in
Unstimulated MC. The incubation of MC with 10μmol/L
rosiglitazone resulted in a marked decrease of MCP-1 mRNA
after a 4 hours’ dwell time (0.09 versus 1) (Figure 2(b)). A
longer incubation time (8 hours) and the use of another
housekeeping gene (GAPDH) resulted in comparable ﬁnd-
ings (data not shown).
3.4. Impact of PPAR-γ Inhibition. In order to investigate
whether the eﬀect of TZD on the mesothelial MCP-1 release
is dependent on the TZD property to activate PPAR-γ,
MC were preincubated with the PPAR-γ inhibitor GW-9662
(10μmol/L) or control media for 24 hours. Afterwards, cells
were incubated with control media, rosiglitazone 10μmol/l,
GW-9662 10μmol/L, or the combination of GW-9662 and
rosiglitazone for 8 hours. In accordance with longer incu-
bation times (Figure 2), rosiglitazone treatment led to a sig-
niﬁcant decrease in MCP-1 protein (1700pg/105 cells versus
control: 2660pg/105 cells; P = 0.028). GW-9662 did not
have an eﬀect on MCP-1 secretion and resulted in similar
MCP-1 protein levels compared to control. The blocking of
PPAR-γ byadministrationofGW-9662beforearosiglitazone
application could completely prevent the rosiglitazone-in-
duced attenuation in MCP-1 release (2870pg/105 cells versus
1700pg/105 cells; P = 0.039) (Figure 4(a)).
Corresponding results could be found on the transcrip-
tional level: whilst rosiglitazone markedly reduced MCP-
1 mRNA levels (0.28 versus 1), PPAR-γ blockade by GW-
9662 resulted in considerably higher MCP-1 mRNA levels
(0.62). GW-9662 alone had no eﬀect on the MC MCP-1
mRNA production, as the administration resulted in a MCP-
1mRNAlevelcomparabletothecontrol(0.86)(Figure4(b)).
3.5. Eﬀect of Rosiglitazone on TNFα-Induced Enhanced Meso-
thelial MCP-1 Release. The incubation of MC with TNFα
(100U/mL) resulted in a drastic increase in mesothe-
lial MCP-1 secretion (67500pg/105 c e l l sv e r s u sc o n t r o l
4000pg/105 cells). Prior incubation with rosiglitazone
10μmol/L and subsequent coincubation resulted in a one-
third reduction in mesothelial MCP-1 levels (43000pg/105
cells versus 67500pg/105 cells) (Figure 5).
4. Discussion
MC are supposed to be critical in the pathogenesis of com-
plications following PD treatment. By producing proﬁbrotic
[13, 14] and neoangiogenetic factors [15], they contribute
to peritoneal ﬁbrosis. In addition, MC are a major source of
intraperitoneal MCP-1 and thus account for the recruitment
of monocytes toward the peritoneal cavity [1]. Apart from
an inﬂammatory reaction, this invasion contributes to peri-
toneal ﬁbrosis by producing various cytokines and growth
factors [2]. MCP-1 can be found in markedly elevated con-
centration in the dialysate of PD patients during and after
episodes of peritonitis [16, 17]. IL-1β,I F N γ,a n dT N F α as
well as high glucose concentrations (due to high osmolality
and the polyol pathway) are found to increase the meso-
thelial MCP-1 synthesis rate [18, 19]. TZD are activators of
PPAR-γ. This receptor is a member of the nuclear receptor
family that includes 48 human transcription factors regu-
lated by direct binding of steroid and thyroid hormones,
vitamins, lipid metabolites, and xenobiotics [20]. By diﬀer-
ential promotor usage and splicing two isoforms are generat-
ed: PPAR-γ1w h i c hc a nb ef o u n do nav a r i e t yo fc e l lt y p e s
and PPAR-γ2, which has an additional 30 amino acids at
its N-terminal end and is expressed speciﬁcally in adipo-
cytes [21]. We could now demonstrate the constitutive ex-
pression of PPAR-γ1 on human MC. In PD patients, there
are some experiences with TZD: Lin et al. described that
rosiglitazone improved glucose metabolism in nondiabetic
uremic patients on CAPD [22], and Wong et al. found
reduced insulin requirement and C-reactive protein levels in4 Mediators of Inﬂammation
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Figure 2: (a) Eﬀect of rosiglitazone on mesothelial MCP-1 release. MC were stimulated with rosiglitazone in the given concentrations for
48 hours. MCP-1 antigen was measured in the cell culture supernatants using ELISA technique. ∗indicates a P value < 0.05; ∗∗indicates a
P value < 0.01 (n = 6). (b) Eﬀect of rosiglitazone on mesothelial MCP-1 mRNA levels. MC were incubated with rosiglitazone 10μMf o r4
hours. Total RNA was extracted and analysed via RT-PCR. MCP-1 mRNA levels were adjusted to the housekeeper rRNA and are expressed
as relative to the control. The ﬁgure is a representative of three independent experiments.
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Figure 3: Eﬀect of rosiglitazone on mesothelial cell viability and proliferation. MC were stimulated with rosiglitazone in the given
concentrations for 48 hours, and then a MTT test was performed as described in the Methods section. Results are described in relation
to the control.
type 2 diabetic patients receiving peritoneal dialysis [23]. In
the present study, we could demonstrate that TZD are able
to reduce the constitutive MCP-1 release in MC by PPAR-γ
stimulation.Furthermore,rosiglitazonewasabletoattenuate
enhanced MCP-1 secretion resulting from a stimulation with
the proinﬂammatory cytokine TNFα.P e n ge ta l .f o u n da
decrease in high glucose concentration-induced mesothelial
production of TGFβ, collagen I, and ﬁbronection secretion
after treatment with troglitazone [14]. Some in vivo animal
model studies point toward positive TZD eﬀects on the
peritoneal membrane in PD or peritoneal inﬂammation:
Yao et al. found maintained peritoneal morphology and in-
creased ultraﬁltration after intraperitoneal administration
of rosiglitazone in comparison to commercial PD solution
alone [24]. Sandoval et al. described a reduction in the
accumulation of AGEs as well as reduced ﬁbrosis and angi-
ogenesis resulting in an improved peritoneal function [25].
In accordance with our ﬁndings, Hornung et al. were able
to demonstrate that the intraperitoneal administration of
ciglitazone was able to signiﬁcantly reduce the number of
invading peritoneal macrophages following a thioglycollate-
induced peritoneal inﬂammation [26]. PPAR-γ stimulation
in MC may be a promising possibility in the attempt to
minimize long-term PD complications. However, potential
negative eﬀects of the TZD (the only commercially available
PPAR-γ activators at present) such as their ability to cause
edema and their negative cardiovascular risk proﬁle [27]
should be considered critically.
5. Conclusions
PPAR-γ1 protein is expressed on human peritoneal MC.
Its activation via rosiglitazone decreases the mesothelial
release and mRNA expression of MCP-1 and attenuates
the TNFα-induced enhancement in MCP-1 release in these
cells. Therefore, the PPAR-γ1 receptor may be a therapeutic
target to ameliorate peritoneal inﬂammation and long-timeMediators of Inﬂammation 5
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Figure 4: (a) PPAR-γ-dependency of the rosiglitazone eﬀect on mesothelial MCP-1 release. MC were preincubated with GW-9662 10μM
for 24 hours (or with control media) and then incubated with the given conditions for 8 hours. Cell supernatants were examined by ELISA.
∗indicates a P value < 0.05 (n = 5). (b) PPAR-γ-dependency of the rosiglitazone eﬀect on mesothelial MCP-1 mRNA expression. MC were
preincubated with GW-9662 10μM for 24 hours (or with control media) and then incubated with the given conditions for 8 hours. Total
RNA was extracted and examined by RT-PCR. The ﬁgure shows a representative experiment out of three independent ones.
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Figure 5: Eﬀect of rosiglitazone on TNFα-induced enhancement of mesothelial MCP-1 secretion. MC were preincubated with rosiglitazone
10μM (white bars) or with control medium (black bars) for 24 hours. Afterwards, the culture media was replaced with media containing
rosiglitazone 10μM (white bars) or not (black bars) to the given conditions. After an incubation time of 8 hours, culture supernatants were
analysed by ELISA (n = 3).
survival of the peritoneal membrane in PD. However, poten-
tialnegativesystemiceﬀectsoftheTZDhavetobeconsidered
critically.
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